On Tuesday, Avidity Biosciences Inc (NASDAQ: RNA) was 1.88% up from the session before settling in for the closing price of $29.33. A 52-week range for RNA has been $21.51 – $56.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 49.32% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -36.54%. With a float of $111.44 million, this company’s outstanding shares have now reached $120.51 million.
In an organization with 391 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 81.04%, operating margin of -3477.44%, and the pretax margin is -2957.72%.
Avidity Biosciences Inc (RNA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Avidity Biosciences Inc stocks. The insider ownership of Avidity Biosciences Inc is 7.55%, while institutional ownership is 103.41%. The most recent insider transaction that took place on May 01 ’25, was worth 190,324. In this transaction Chief Program Officer of this company sold 5,875 shares at a rate of $32.40, taking the stock ownership to the 50,554 shares. Before that another transaction happened on May 01 ’25, when Company’s Officer proposed sale 5,875 for $32.65, making the entire transaction worth $191,819.
Avidity Biosciences Inc (RNA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -36.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.72% during the next five years compared to -34.37% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
You can see what Avidity Biosciences Inc (RNA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 16.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 403.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.01, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -4.41 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.56 million. That was better than the volume of 1.48 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 42.90%. Additionally, its Average True Range was 2.38.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 56.29%, which indicates a significant increase from 53.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.74% in the past 14 days, which was higher than the 71.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.52, while its 200-day Moving Average is $36.99. However, in the short run, Avidity Biosciences Inc’s stock first resistance to watch stands at $30.51. Second resistance stands at $31.15. The third major resistance level sits at $32.31. If the price goes on to break the first support level at $28.71, it is likely to go to the next support level at $27.55. Assuming the price breaks the second support level, the third support level stands at $26.91.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
There are 120,520K outstanding shares of the company, which has a market capitalization of 3.60 billion. As of now, sales total 10,900 K while income totals -322,300 K. Its latest quarter income was 1,570 K while its last quarter net income were -115,770 K.
